Skip to main content

Table 8 AMSTAR 2 classification of included studies

From: Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews

StudyYearItem1Item2Item3Item4Item5Item6Item7Item8Item9Item10Item11Item12Item13Item14Item15Item16Grade
Yongfei Chen [14]2013YPNYNYYYYNYYYYNNlow
Musini VM [8]2017YYYYYYYYYYYYYYYYhigh
Gao D [15]2011YYYYYYYYYYYYYYYYhigh
Zhenfeng Zheng [16]2011YYNYNYYYYYYYYYYYmoderate
Verdecchia P [17]2010YPNYNYYYNYYNNNNYcritically low
Powers B [18]2011YPNYNNYNYYYYYYNYlow
Stanton AV [19]2010YPNNNNPPNYYNNNNYcritically low
Luo Y [20]2018YYYYNNYYYYYYYYNYlow
Zhang JT [21]2015YYYYYYYYYNYYYYYYhigh
Zheng SL [22]2017YYNYYYYYYYYYYYNYlow
Gradman AH [23]2010YYNNNNNYNYYNNYNNcritically low
White WB [24]2011YPNYNNNNNYYNNYNYcritically low
Rizos EC [25]2012YPNNNYYPNYYYNYNYcritically low
Louvis N [26]2018YPNNNYNYYYYNNYNYcritically low
  1. Note: Abbreviations: Y Yes, N No, P Partial